InnoCan PharmaHAM:IP40 +9.74%59 Buyback Yield % is -1.10 as of Jul. 02, 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 59/100 and a GF Value™ of €9.23 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 556 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 64.21% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for InnoCan Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Buyback Yield % Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Buyback Yield % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (HAM:IP40) has a Buyback Yield % of -1.10 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #357 out of 556 companies in the Consumer Packaged Goods industry, placing it in the top 64.2%.
Is InnoCan Pharma's Buyback Yield % too high?
InnoCan Pharma's current Buyback Yield % is -1.10. Based on the distribution chart, InnoCan Pharma ranks #357 out of 556 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Buyback Yield % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #357 out of 556 companies for Buyback Yield %. This places InnoCan Pharma in the lower half of its industry. The industry median Buyback Yield % is 0.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Consumer Packaged Goods company?
The median Buyback Yield % among Consumer Packaged Goods companies is 0.01, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Buyback Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Buyback Yield % is -1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.23, compared to a current price of €1.47 — trading 84.1% below its estimated fair value. The current Buyback Yield % is -1.10. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Buyback Yield % is -1.10 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.47 is trading 84.1% below its estimated GF Value™ of €9.23.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Buyback Yield %: -1.10
GF Value™: €9.23 vs. price of €1.47 (84.1% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
59GF Score
Get the complete analysis for HAM:IP40
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
